Stroke in adults with primary intracranial tumours

Gerald T. Finnerty,Stuart C Innes,Lucia Yin

DOI: https://doi.org/10.1101/2024.10.06.24314978

2024-10-07

Abstract:BACKGROUND: Malignant primary intracranial tumours are associated with stroke. Knowing how stroke differs in patients with either benign or malignant primary intracranial tumours would give insights into how intracranial tumours affect stroke and would help to improve the limited stroke guidelines for these patients. METHODS: We conducted a retrospective cohort study of patients with benign or malignant primary intracranial tumours admitted with stroke (2011 - 2022) to a single centre with regional stroke and neuro-oncology units. Data collected included: stroke aetiology, stroke timing relative to tumour diagnosis, pre-stroke disability, post-stroke disability, stroke recurrence and treatment. RESULTS: We identified 258 patients who had an index stroke (120 haemorrhagic, 135 ischaemic, three coincident haemorrhagic/ischaemic) at or after the diagnosis of their primary intracranial tumour (71% benign, 29% malignant). Symptomatic intracranial haemorrhage was more commonly associated with malignant primary intracranial tumours. Patients with a malignant primary intracranial tumour were 2.7 times more likely to have a stroke than patients with a benign intracranial tumour. We estimated that the risk of ischaemic stroke and symptomatic intracranial haemorrhage within six months of diagnosis of a benign primary intracranial were respectively 2.5 and 5.0 times that of the general population. In-hospital mortality and level of disability at hospital discharge (median modified Rankin scale score, 4) were similar for patients with benign or malignant primary intracranial tumours. Stroke recurrence was 22% at one year. Statins were associated with reduced stroke recurrence. Patients with malignant tumours and high post-stroke disability were less likely to receive chemotherapy after hospital discharge. CONCLUSIONS: Our findings suggest that stroke is a wider issue for patients with primary intracranial tumours than commonly recognised. Our data indicated that statins may help to prevent stroke recurrence. Despite concerns about intracranial haemorrhage, antiplatelet agents should be considered after ischaemic stroke.